Pharmaceuticals News and Research

RSS

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Cipher Pharmaceuticals Inc. today announced that the U.S. Patent and Trademark Office has issued a Patent Notice of Allowance for CIP-TRAMADOL ER, the Company's extended-release tramadol product for the treatment of moderate to moderately severe chronic pain in adults.

8 Oct 2010

ARCA receives European Patent for bucindolol based treatment for heart failure

ARCA biopharma, Inc. a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, today announced that the European Patent Office has issued a patent on methods of treating heart failure patients with bucindolol based on genetic targeting.

8 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Onyx Pharmaceuticals, Inc. today announced that it will delay its New Drug Application (NDA) filing for carfilzomib based on a recent meeting with the Chemistry, Manufacturing and Controls (CMC) review division of the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Cyclacel announces completion of private placement sale

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced today that it consummated its previously announced private placement to sell approximately $15.2 million of its units to several institutional investors, including the Special Situations Funds, for net proceeds of approximately $14.1 million after the deduction of offering expenses.

7 Oct 2010

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

7 Oct 2010

Humana Pharmacy agrees to highest standards of transparency for prescription-drug pricing

Humana Inc. announced today that its Humana Pharmacy Solutions division is one of only five pharmacy-benefit managers (PBMs) in the U.S. to agree to the highest level of transparency for prescription-drug pricing set by the HR Policy Association.

7 Oct 2010

Sucampo submits marketing application for Amitiza drug

Sucampo Pharmaceuticals, Inc. and Abbott today announced that Sucampo Pharma Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc., has submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market Amitiza (lubiprostone) 24 mcg for the treatment of chronic idiopathic constipation (CIC).

7 Oct 2010

DSM project on carbon dioxide footprint reduction receives European Outsourcing Awards

DSM Pharmaceutical Products, the custom manufacturing organization of Royal DSM NV, is pleased to announce that their submission for the European Outsourcing Awards, organized by Via Media UK Ltd, entitled Achieving substantial carbon dioxide footprint reduction for the scale up of a drug intermediate was an award recipient at the 6th October ceremony held in Paris, France.

7 Oct 2010

Soy germ-based nutritional supplement helps to manage menopausal symptoms

A new women-s health, whole soy germ-based nutritional supplement containing Natural S-equol reduced the frequency of moderate to severe hot flashes and reduced muscle and joint pain in the first study of its kind among postmenopausal U.S. women, according to peer-reviewed data presented as a poster presentation at the North American Menopause Society (NAMS) Annual Meeting.

7 Oct 2010

AstraZeneca provides free medicines to patients at Primary Care Center Pharmacy in Sacramento

AstraZeneca announced today that it is providing medicines at no cost to qualifying patients at the Primary Care Center Pharmacy in Sacramento, California.

7 Oct 2010

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Cortex Pharmaceuticals, Inc. announced that the rights to a published patent application entitled, "Pharmacological Modulation of Positive AMPA Receptor Modulator Effects on Neurotrophin Expression", has been licensed exclusively to Cortex from the University of California.

7 Oct 2010

Quintiles, SNUH announce clinical research partnership

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today celebrated its 10th year anniversary in South Korea by announcing a strategic alliance with the Seoul National University Hospital (SNUH) as part of its unique Prime Site program. SNUH is Quintiles' second Prime Site in Asia, adding to six other existing sites located in the United States, Europe and Africa.

7 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

Neoprobe completes pre-NDA assessment for Lymphoseek with FDA

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has completed a pre-NDA assessment for Lymphoseek with the U.S. Food and Drug Administration (FDA).

7 Oct 2010

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis, a global specialty pharmaceutical company focused on therapeutic products for chronic respiratory and immune disorders, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market ARIDOL™ (mannitol inhalation powder) Bronchial Challenge Test Kit, the first new bronchial challenge test in more than two decades.

7 Oct 2010

Gymnemic acid nanocrystals could help develop soluble drug compounds

Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.

7 Oct 2010

BioNJ creates special diagnostics committee to focus on personalized medicine

The strength of New Jersey's life sciences community and its unique ability to contribute to one of medicine's fastest growing areas—personalized medicine—has prompted BioNJ, the voice of the biotechnology industry in New Jersey, to create a special Diagnostics Committee.

7 Oct 2010

3.5 million Calif. residents eligible for tax credits in future exchange; N.Y. prescription drug aid for seniors cut back; Idaho trims dental providers in Medicaid

An estimated 3.5 million Californians would be eligible for federal tax credits to slash the cost of their health coverage when they begin buying policies through a new statewide insurance marketplace in 2014, a study released Tuesday found.

7 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

Pharmaceuticals News and Research

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

ARCA receives European Patent for bucindolol based treatment for heart failure

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Onyx Pharmaceuticals announces delay in NDA filing for carfilzomib

Cyclacel announces completion of private placement sale

Bayer HealthCare, Onyx to present data on Nexavar tablets at ESMO Congress

Humana Pharmacy agrees to highest standards of transparency for prescription-drug pricing

Sucampo submits marketing application for Amitiza drug

DSM project on carbon dioxide footprint reduction receives European Outsourcing Awards

Soy germ-based nutritional supplement helps to manage menopausal symptoms

AstraZeneca provides free medicines to patients at Primary Care Center Pharmacy in Sacramento

Cortex secures patent rights for combined use of AMPAKINE and mGluR5 compounds for Fragile X syndrome treatment

Quintiles, SNUH announce clinical research partnership

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Neoprobe completes pre-NDA assessment for Lymphoseek with FDA

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Gymnemic acid nanocrystals could help develop soluble drug compounds

BioNJ creates special diagnostics committee to focus on personalized medicine

3.5 million Calif. residents eligible for tax credits in future exchange; N.Y. prescription drug aid for seniors cut back; Idaho trims dental providers in Medicaid

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence